Interaction of mephedrone with dopamine and serotonin targets in rats

European Neuropsychopharmacology

Volumn 22, Issue 3, 2012, Pages 231-236

  Martínez Clemente, José ^a   Escubedo, Elena ^a   Pubill, David ^a   Camarasa, Jorge ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Dopamine; Mephedrone; Serotonin

Indexed keywords

3BETA (4 FLUOROPHENYL) 2BETA TROPANECARBOXYLIC ACID METHYL ESTER; 4' METHYLMETHCATHINONE; AMFEBUTAMONE; APROTININ; ASCORBIC ACID; BENZYLSULFONYL FLUORIDE; CLOMIPRAMINE; COCAINE; DEXAMPHETAMINE; DOPAMINE; DOPAMINE 2 RECEPTOR; FLUOXETINE; KETANSERIN; METHYSERGIDE; PARGYLINE; PAROXETINE; PINDOLOL; RACLOPRIDE; SEROTONIN; SEROTONIN 2 RECEPTOR; SULPIRIDE; VANADATE SODIUM;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; CORPUS STRIATUM; DOPAMINE UPTAKE; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR AFFINITY; SYNAPTOSOME;

ANIMALS; CEREBRAL CORTEX; CORPUS STRIATUM; DOPAMINE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; DOSE-RESPONSE RELATIONSHIP, DRUG; MALE; METHAMPHETAMINE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, DOPAMINE; RECEPTORS, SEROTONIN; SEROTONIN; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; SYNAPTOSOMES;

EID: 84856538825     PISSN: 0924977X     EISSN: 18737862     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2011.07.009     Document Type: Article

References (19)

1. Battaglia G., Brooks B.P., Kulsakdinun C., De Souza E.B. Pharmacologic profile of MDMA (3,4-methylenedioxymethamphetamine) at various brain recognition sites. Eur. J. Pharmacol. 1988, 149:159-163.
2. Camilleri A., Johnston M., Brennan M., Davis S., Caldicott D. Chemical analysis of four capsules containing the controlled substance analogues 4-methylmethcathinone, 2-fluoromethamphetamine, alpha-phthalimidopropiophenone and N-ethylcathinone. Forensic Sci. Int. 2010, 197:59-66.
3. Capela J.P., Carmo H., Remião F., Bastos M.L., Meisel A. Molecular and cellular mechanisms of ecstasy-induced neurotoxicity: an overview. Mol. Neurobiol. 2009, 39:210-271.
4. Chipana C., Camarasa J., Pubill D., Escubedo E. Protection against MDMA induced dopaminergic neurotoxicity in mice by methyllycaconitine: involvement of nicotinic receptors. Neuropharmacology 2006, 51:885-895.
5. Colado M.I., O'Shea E., Granados R.R., Esteban B.B., Martín A.B., Green A.R. Studies on the role of dopamine in the degeneration of 5-HT nerve endings in the brain of Dark Agouti rats following 3,4-methylenedioxymethamphetamine (MDMA or 'ecstasy') administration. Br. J. Pharmacol. 1999, 126:911-924.
6. Cozzi N.V., Sievert M.K., Shulgin A.T., Jacobill P., Rhuolo A.E. Inhibition of plasma membrane monoamine transporters by betaketoamphetamines. Eur. J. Pharmacol. 1999, 381:63-69.
7. Escubedo E., Abad S., Torres I., Camarasa J., Pubill D. Comparative neurochemical profile of 3,4-methylenedioxymethamphetamine and its metabolite alpha-methyldopamine on key targets of MDMA neurotoxicity. Neurochem. Int. 2011, 58:92-101.
8. Escubedo E., Chipana C., Pérez-Sánchez M., Camarasa J., Pubill D. Methyllycaconitine prevents methamphetamine-induced effects in mouse striatum: involvement of alpha7 nicotinic receptors. J. Pharmacol. Exp. Ther. 2005, 315:658-667.
9. Green A., Richard A.R., Mechan A.O., Eliott J., Martin J.M., O'Shea E., Colado M.I. The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy"). Pharmacol. Rev. 2003, 55:463-508.
10. Hrometz S.L., Brown A.W., Nichols D.E., Sprague J.E. 3,4-methylenedioxymethamphetamine (MDMA, ecstasy)-mediated production of hydrogen peroxide in an in vitro model: the role of dopamine, the serotonin-reuptake transporter, and monoamine oxidase-B. Neurosci. Lett. 2004, 367:56-59.
11. Kehr J., Ichinose F., Yoshitake S., Goiny M., Sievertsson T., Nyberg F., Yoshitake T. Mephedrone, compared to MDMA (ecstasy) and amphetamine, rapidly increases both dopamine and serotonin levels in nucleus accumbens of awake rats. Br. J. Pharmacol. 2011, 164:1949-1958.
12. McElrath K., O'Neill C. Experiences with mephedrone pre- and post-legislative controls: perceptions of safety and sources of supply. Int. J. Drug Policy 2011, 22:120-127.
13. Measham F., Moore K., Newcombe R., Welch Z. Tweaking, bombing, dabbing and stockpiling: the emergence of mephedrone and the perversity of prohibition. Drugs Alcohol Today 2010, 10:14-21.
14. Nagai F., Nonaka R., Sato H., Kamimura K. The effects of non-medically used psychoactive drugs on monoamine neurotransmission in rat brain. Eur. J. Pharmacol. 2007, 559:132-137.
15. Pubill D., Chipana C., Camins A., Pallàs M., Camarasa J., Escubedo E. Free radical production induced by methamphetamine in rat striatal synaptosomes. Toxicol. Appl. Pharmacol. 2005, 204:57-68.
16. Saunders C.C., Ferrer J.V., Shi L., Chen J., Merrill G. Amphetamine-induced loss of human dopamine transporter activity: an internalization-dependent and cocaine-sensitive mechanism. Proc. Natl. Acad. Sci. U. S. A. 2000, 97:6850-6855.
17. Schifano F., Albanese A., Fergus S., Stair J.L., DeLuca P., Corazza O. Mephedrone (4-methylmethcathinone; 'meow meow'): chemical, pharmacological and clinical issues. Psychopharmacology 2011, 214:593-602.
18. Sprague J.E., Everman S.L., Nichols D.E. An integrated hypothesis for the serotonergic axonal loss induced by 3,4-methylenedioxymethamphetamine. Neurotoxicology 1998, 19:427-441.
19. Winstock A., Mitcheson L., DeLuca P., Davey Z., Corazza O., Schifano F. Mephedrone, new kid for the chop?. Addiction 2011, 106:154-161.